VIDO-InterVac at the University of Saskatchewan is a leading organization in vaccine development, particularly noted for its work on infectious diseases affecting both humans and animals. The organization has a strong focus on creating subunit vaccines, such as COVAC-2, which is designed to combat COVID-19. This vaccine utilizes purified viral proteins that are non-infectious, allowing for easier storage and distribution compared to mRNA vaccines that require ultra-cold temperatures. VIDO's expertise in vaccine formulation is further enhanced by collaborations with international partners, which have contributed to the development of adjuvants that improve immune responses. The organization operates under stringent good manufacturing practices (GMP) and is equipped with state-of-the-art containment facilities, enabling it to conduct advanced research and clinical trials.

In addition to human health, VIDO-InterVac is also dedicated to cross-species research, particularly in equine health, where findings can lead to solutions applicable to both horses and humans. The organization is actively investigating viral respiratory diseases in horses, leveraging knowledge gained from equine studies to inform human health initiatives. VIDO's commitment to addressing emerging infectious diseases, such as West Nile virus, underscores its role as a pivotal player in global health research. With substantial government support and a robust infrastructure, VIDO is positioned to significantly impact vaccine development and infectious disease control on both national and international levels.

Canada

To strengthen Canada’s role in responding to infectious diseases, the University of Saskatchewan's Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) works with international partners to study human and animal pathogens and develop solutions.With 150 interdisciplinary personnel, over $200 million in containment infrastructure, and more

VIDO-InterVac, University of Saskatchewan

Company Details